Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Nature | Jul 26, 2012

Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour micro-environment confers innate resistance to therapy. Here we developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs. We found that stroma-mediated resistance is common, particularly to targeted agents. We characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance. Proteomic analysis showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signalling pathways, and immediate resistance to RAF inhibition. Immunohistochemistry experiments confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment. Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma. A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines. More generally, this study indicates that the systematic dissection of interactions between tumours and their micro-environment can uncover important mechanisms underlying drug resistance.

Pubmed ID: 22763439 RIS Download

Mesh terms: Antineoplastic Agents | Antineoplastic Combined Chemotherapy Protocols | Cell Line, Tumor | Coculture Techniques | Drug Resistance, Neoplasm | Hepatocyte Growth Factor | Humans | Indoles | Melanoma | Molecular Targeted Therapy | Mutation | Phosphatidylinositol 3-Kinases | Prognosis | Protein Kinase Inhibitors | Proteomics | Proto-Oncogene Proteins B-raf | Proto-Oncogene Proteins c-met | Signal Transduction | Stromal Cells | Sulfonamides | Tumor Microenvironment

Research tools detected in this publication

Data used in this publication

Associated grants

  • Agency: NCI NIH HHS, Id: UM1 CA186709
  • Agency: NCI NIH HHS, Id: P50 CA093683
  • Agency: NCI NIH HHS, Id: U54CA112962
  • Agency: NCI NIH HHS, Id: R01 CA166480
  • Agency: Howard Hughes Medical Institute, Id: U54 CA112962
  • Agency: NCI NIH HHS, Id: P50CA093683
  • Agency: NCI NIH HHS, Id:

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.

Broad Institute

A biomedical and genomic research center that is independently governed that encompasses three types of organizational units: core member laboratories, programs and platforms which work together and with other collaborators to tackle critical problems in human biology and disease. Data and cutting edge software tools are generated and developed, and these tools analyze those data (increasingly large genome-related datasets) which is shared openly with the scientific community. The Broad faculty includes core members and associate members. All associate members hold primary appointments in a home department at one of the partner institutions, but are deeply involved in the scientific work and culture of the Broad Institute. It is formally affiliated with the Massachusetts Institute of Technology, Harvard University and its affiliated hospitals.


View all literature mentions